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ABSTRACT 
 
Purpose: Patient-reported outcomes (PROs) can promote patient-centered care in multiple ways: 
(1) using an individual patient’s PRO data to inform his/her management, (2) providing PRO 
results from comparative research studies in patient educational materials/decision aids, and (3) 
reporting PRO results from comparative research studies in peer-reviewed publications.  Patients 
and clinicians endorse the value of PRO data; however, variations in how PRO measures are 
scored and scaled, and in how the data are reported, make interpretation challenging and limit 
their use in clinical practice.  We conducted a modified-Delphi process to develop stakeholder-
engaged, evidence-based recommendations for PRO data display for the three above applications 
to promote understanding and use.   
 
Methods: The Consensus Panel included cancer survivors/caregivers, oncologists, PRO 
researchers, and application-specific end-users (e.g., electronic health record vendors, decision 
aid developers, journal editors).  We reviewed the data display issues and their evidence base 
during pre-meeting webinars.  We then surveyed participants’ initial perspectives, which 
informed discussions during an in-person meeting to develop consensus statements.  These 
statements were ratified via a post-meeting survey.   
 
Results:  Issues addressed by consensus statements relevant to both individual- and research-
data applications were directionality (whether higher scores are better/worse) and conveying 
score meaning (e.g., none/mild/moderate/severe). Issues specific to individual-patient data 
presentation included representation (bar charts vs. line graphs) and highlighting possibly 
concerning scores (absolute and change). Issues specific to research-study results presentation 
included handling normed data, conveying statistically significant differences, illustrating 
clinically important differences, and displaying proportions improved/stable/worsened.   
 
Conclusions: The recommendations aim to optimize accurate and meaningful interpretation of 
PRO data. 
 
 
Key Words: patient-reported outcomes, consensus statements, cancer, data display, clinical 
practice 
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INTRODUCTION 
With the increasing emphasis on patient-centered care, patients’ perspectives, collected using 
standardized patient-reported outcomes (PRO) measures of, for example, symptoms, functional 
status, and well-being, are playing a greater role in clinical care and research [1-8].  There are 
multiple applications of PRO data, including, among others, (1) using an individual patient’s data 
to inform his/her care; (2) providing PRO results from comparative research studies (e.g., clinical 
trials) in patient educational materials and decision aids to inform patients’ understanding of the 
patient-centered outcomes associated with different treatment options; and (3) reporting PRO 
results from comparative research studies in peer-reviewed publications to inform clinicians of 
the treatment impacts, both for their own knowledge and for counseling patients. 
 
Both patients and clinicians endorse the value of PROs in the three applications described above, 
but they also report challenges interpreting the meaning and implications of PRO data [9-11].  
These challenges result in part from the lack of standardization in how PRO measures are scored 
and scaled, and in how the data are reported.  For example, on some PRO questionnaires, higher 
scores are always better; on other PRO questionnaires, higher scores reflect “more” of the 
outcome and are therefore better for function domains but worse for symptoms.  Some PRO 
measures are scaled 0-100, with the best and worst outcomes at the extremes, whereas others are 
normed to, for example, a general population average of 50.  There are also variations in how 
PRO results are reported – in some cases as mean scores over time, in other cases as the 
proportion of patients meeting a responder definition (improved/stable/worsened).  The 
challenges in interpreting PRO results limit patients’ and clinicians’ use of the data in clinical 
practice.   
 
In previous research, we investigated different approaches for displaying PRO data for the three 
applications described above (individual patient data, research data presented to patients, 
research data presented to clinicians) to identify the graphical formats that were most accurately 
interpreted and rated the clearest [12-17].  At the conclusion of that research study, that study’s  
Stakeholder Advisory Board (SAB) advised that the evidence generated was sufficient to inform 
the development of recommendations for PRO data display for those three applications and 
suggested that we engage a broader group of stakeholders via a consensus process to develop the 
recommendations.  This paper reports on the results of that project. 
 
METHODS 
We conducted a stakeholder-driven, evidence-based, modified-Delphi process to develop 
recommendations for displaying PRO data in three different applications: individual patient data 
for monitoring/management, research results presented to patients in educational 
materials/decision aids, and research results presented to clinicians in peer-reviewed 
publications.  We used a standard modified-Delphi approach, consisting of a pre-meeting survey 
relevant to the application of interest, a face-to-face meeting, and a post-meeting survey.  The 
first two applications were addressed during an in-person meeting in February 2017, and the 
third application was addressed during an in-person meeting in October 2017.  For simplicity, we 
refer to these as Meeting #1 and #2.  The meetings addressed different applications; issues that 
were relevant across applications were handled in the context of each application separately. 
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Because much of the evidence base guiding this process emerged from studies in oncology, we 
focused specifically on the cancer context.  In addition to the project team and this project’s 
SAB, we purposefully invited representatives from key stakeholder groups: cancer 
patients/caregivers, oncology clinicians, PRO researchers, and stakeholders specific to particular 
applications (e.g., electronic health record vendors for individual patient data, decision aid 
experts for research data presented to patients, journal editors for research data presented to 
clinicians). 
 
Prior to each in-person meeting, we held a webinar during which we oriented participants to the 
purpose of the project, the specific data display issues that we were addressing for the relevant 
applications (Table 1, column 1), and the evidence base regarding the options for those data 
display issues.  The following parameters informed the considerations: (1) recommendations 
should work on paper (static presentation); (2) presentation in color is possible (but it should be 
interpretable in grayscale); and (3) additional functionality in electronic presentation is possible 
(but not part of standards).  Notably, during the meeting discussions, additional guiding 
principles were established: (1) displays should be as simple and intuitively interpretable as 
possible; (2) it is reasonable to expect that clinicians will need to explain the data to patients; and 
(3) education and training support should be encouraged to be available. 
 
After the pre-meeting webinar, we surveyed participants’ initial perspectives using Qualtrics, a 
leading enterprise survey company, with protections for sensitive data, used by colleges and 
universities around the world [18].  Specifically, for each issue, we first asked participants to rate 
whether there ought to be a standard on that topic.  Response options were Important to Present 
Consistently, Consistency Desirable, Variation Acceptable, and Important to Tailor to Personal 
Preferences.  Regardless of their response to this question, we asked participants to indicate what 
the standard should be, with alternative approaches for addressing that particular issue as the 
response options.  For example, for data presented to patients, the options for presenting 
proportions included pie charts, bar charts, and icon arrays, based on the available evidence base 
[16].  Following each question, participants were asked to indicate the rationale behind their 
responses in text boxes.  A summary of the pre-meeting survey results and comments was 
circulated prior to the meeting. 
 
At each in-person meeting, we addressed each of the data display issues, briefly summarizing the 
evidence base and the feedback from the pre-meeting survey before opening up the topic for 
discussion.  At Meeting #1, the participants aimed to be consistent across the two applications, 
when possible.  For Meeting #1 topics also addressed during Meeting #2, after an initial 
discussion, the consensus statements from Meeting #1 were shared for the Meeting #2 group’s 
consideration, with the possibility of accepting the statement unchanged, modifying it, discarding 
it, or developing a new statement.   
 
Following the discussion, participants voted using an audience response system (to ensure 
anonymity) on whether there should be a standard, and in cases where a standard was supported, 
what that standard should be.  Issues that were not considered appropriate for a standard, and 
topics for further research, were also noted.  After the meeting, the consensus statements were 
circulated to participants via Qualtrics.  Each participant was asked whether each consensus 
statement was “acceptable” or “not acceptable,” and if the latter, to indicate why in a text box. 
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The funders had no role in the project design; data collection, analysis, or interpretation; writing; 
or decision to submit this manuscript for publication. 
 
RESULTS 
There were 28 participants on the Meeting #1 Consensus Panel, and a slightly different set of 27 
participants on the Meeting #2 Consensus Panel (See Acknowledgements and Appendix Table 
1).  The panel included (not mutually exclusive): 15 doctor or nurse clinicians, 10 participants 
who identified as patient or caregiver advocates, 12 participants with PhDs, and 6 members of 
journal editorial boards.  There were 22 females and 14 males.  Of the 28 Meeting #1 
participants, 26 completed the pre-meeting survey, 22 attended the in-person meeting, and all 28 
completed the post-meeting survey.  Of the 27 Meeting #2 participants, 26 completed the pre-
meeting survey, 18 attended the in-person meeting, and 26 completed the post-meeting survey.   
 
Post-meeting endorsement of the Meeting #1 draft consensus statements ranged from 89%-
100%, and for Meeting #2 ranged from 88%-100%, across the recommendations.  Table 1 
displays the consensus statements for each of the three applications, with the final column 
commenting on differences across applications, where relevant.  Table 2 reports the areas 
identified for further research.  Figures 1-3 illustrate an implementation of the recommendations 
for line graphs for each of the three applications, respectively. 
 
There were two issues that were addressed for all three applications: directionality of PRO score 
display and conveying score meaning.  Across the three applications, the Consensus Panels 
agreed that the two different ways people interpret a line going up for symptoms (some expect 
“up” to always be better, others expect “up” to indicate more of the symptom) creates challenges 
for interpretation.  Both Consensus Panels recommended using exceptionally clear labeling, 
titling, and other annotations to address this potential confusion, and warned against mixing 
score direction in a single display (i.e., a single figure).  Whereas the Meeting #1 Consensus 
Panel advised against any change in how PRO scores are displayed to make the direction 
consistent, the Meeting #2 Consensus Panel could envision rare circumstances in journal 
publications where changing the directionality of display for consistency would be appropriate 
(e.g., when only one of many outcomes is scored in the opposite direction).  However, the Panel 
noted that, in those cases, it is important that meta-analyses can identify the original scores in the 
publication.  The Consensus Panels agreed that further research is needed regarding how to 
address the inherent confusion associated with inconsistency in directionality across instruments.   
 
For conveying score meaning, across the three applications, the Consensus Panels agreed that 
descriptive labels (e.g., none/mild/moderate/severe) along the y-axis are helpful and should be 
used when data exist to support their placement on the scale.  The Meeting #1 Consensus Panel 
explicitly stated that placement of the extremes (e.g., none/severe) could be included and 
acknowledged that evidence regarding placement of the middle categories (e.g., mild/moderate) 
might not be available.  Specifically, the extreme categories (e.g., none, severe) can generally be 
placed at the lowest and highest scores, but, for many PRO measures, the score ranges that 
would be considered mild or moderate, for example, may not have been established.  That is, it is 
not always clear at what point on the score continuum a symptom becomes mild or moderate.   
The Meeting #2 Consensus Panel felt this elaboration regarding the lack of evidence supporting 
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placement of the middle categories was implied by the first statement.  Both Consensus Panels 
noted the need for further research regarding the best methods for identifying the score ranges 
associated with the descriptive labels.  The Meeting #1 Consensus Panel recommended including 
reference values for comparison populations, when available, for presenting either individual-
level data or research data to patients.   The Meeting #2 Consensus Panel took a softer approach, 
recommending only that inclusion of the reference values be considered. 
 
For issues specific to individual patient data (Application 1), the Consensus Panel recommended 
showing line graphs of scores over time and including some indication of possibly concerning 
results in absolute terms (where evidence exists to support the concerning PRO score range).  
The Consensus Panel noted the need for more research regarding how to display possibly 
concerning changes.  There was some discussion of whether the slope of the line would be 
sufficient to convey important worsening.  An issue was also raised during the discussions 
regarding whether it is important that the time points displayed on the x-axis be proportional to 
the time elapsed; this topic was recommended for further research. 
 
For presentation of research results, both to patients and to clinicians (Applications 2 and 3), the 
Consensus Panels addressed normed scoring, conveying clinically important differences, and 
displaying the proportion meeting a responder definition (i.e. improved/stable/worsened).  Both 
Consensus Panels agreed that PRO data display should accommodate both normed and non-
normed scoring.  While there were some minor differences in the consensus statement wording, 
they also agreed that display of the norm is optional, depending on the trade-offs between added 
interpretive value vs. potentially greater complexity.  They also noted that information about the 
norm may be less relevant in the context where the focus is on the comparison between treatment 
options.  Across both applications, if a norm is shown, which norm to show must be decided (to 
the extent options are available), and it is important to describe the reference population and 
label the norm clearly.  For presentation to patients, it is also necessary to explain that the 
reference population may not be applicable to a given patient.  Given the evidence presented to 
the Meeting #1 Consensus Panel, which demonstrated challenges accurately interpreting normed 
scores for presentation to patients [16], the Meeting #1 Consensus Panel also recommended 
further research investigating how to handle normed scores for this application of PRO data. 
 
The Meeting #1 Consensus Panel agreed that it is important to present to patients information 
regarding clinically important differences between treatments, but felt that further research was 
needed to determine the best approaches for doing so.  The Meeting #2 Consensus Panel 
recommended indicating clinically important differences in journal publications using some sort 
of symbol (described in a legend), but not an asterisk due to its association with statistical 
significance.  They also advised reporting in the legend and/or in the text of the paper when the 
clinically meaningful difference for a PRO measure is unknown.   
 
For proportions meeting a responder definition, for presentation to patients (Application 2), the 
Meeting #1 Consensus Panel recommended using pie charts and indicating the proportion 
numerically.  For presentation to clinicians in journal publications, the Meeting #2 Consensus 
Panel agreed that the results should be presented visually but did not recommend a single format 
for doing so, noting that bar charts, pie charts, and stacked bar charts are reasonable approaches.  
The difference between the recommendations for the two applications resulted from differences 
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in the evidence base [16-17].  Specifically, the data strongly supported pie charts over the other 
options for presenting data to patients, but there was no clear advantage between pie charts and 
bar charts for presenting data to clinicians.   
 
The issue of conveying statistical significance was uniquely addressed for presentation of 
research data to clinicians (Application 3).  The Consensus Panel recognized the conflict 
between evidence demonstrating that clinicians and others appreciate p-values vs. the move 
away from reporting p-values to reporting confidence intervals.  They concluded that, regardless 
of whether p-values are reported, confidence intervals should always be displayed.  For example, 
on line graphs confidence limits can be used for individual timepoints, with p-values for the 
overall difference between treatments over time. 
 
 
DISCUSSION 
PRO data have enormous potential to promote patient-centered care, but for this potential to be 
realized, it is critical that clinicians and patients understand what the scores mean.  Guided by the 
evidence-base from the literature, we conducted a modified-Delphi consensus process to develop 
recommendations for PRO data display to promote understanding and use in practice.   
 
Strengths of the process include the engagement of a broad range of key stakeholders.  To ensure 
all panelists could provide their input anonymously, we conducted pre-meeting and post-meeting 
surveys, and used an audience response system at the in-person meetings.  The modified Delphi 
methodology facilitated the development of the consensus recommendations.  One limitation of 
this process is that it focused on the cancer context specifically, given that much of the evidence-
base resulted from oncology studies.  Further research is needed to investigate whether there are 
any differences in the underlying evidence in different patient populations, including those with 
lower literacy, that would necessitate modifications to these recommendations for PROs.  
Notably, other clinical data from trials also need careful presentation and clear messaging to 
enable communication and interpretation, but this project focused specifically on PROs.   
 
We limited the process to display recommendations that would work on paper and could be 
interpreted in grayscale.  The additional functionalities that are becoming increasingly feasible 
with electronic data display were not considered, and would be appropriate for future 
recommendation development.  To the extent possible, the Consensus Panels aimed to provide 
consistent recommendations across the three applications.  When recommendations differed by 
application, this was generally driven by variation in needs of the target audience in that specific 
context.  While these recommendations apply to current domain-scored PRO measures, as novel 
PRO instruments are developed, alternative approaches to data display may be required.   
 
This consensus process produced clear guidance for graphically displaying PRO data and 
identified areas requiring further research.  Next steps include working with stakeholders and 
developing tools (e.g., templates) to facilitate the implementation of these recommendations in 
practice – and evaluating their impact.  The long-term goal is to promote patient-centered care by 
optimizing accurate and meaningful interpretation of PRO results. 
 
COMPLIANCE WITH ETHICAL STANDARDS 
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Table 1: Summary of Consensus Statements (by Issue and Application) a,b 
 Meeting #1 Meeting #2  
Issue Application 1: 
Individual Patient Data  
Application 2: 
Research Results Presented to 
Patients (i.e. Educational Materials 
and Decision Aids) 
 
Application 3: 
Research Results Presented to Clinicians (i.e. 
Peer-Reviewed Publications) 
Comments 
Directionality 
of PRO Scores  
There is no easy solution to the issue of directionality.  There is a split in the 
“intuitive” interpretation of symptom scores, with some people expecting 
that higher scores would be “better” and others expecting that higher scores 
would be “more” of the symptom (and, therefore, worse). 
The Consensus Panel acknowledges the challenges 
associated with directionality.  There is a split in the 
“intuitive” interpretation of symptom scores, with 
some people expecting that higher scores would be 
“better” and others expecting that higher scores 
would be “more” of the symptom (and, therefore, 
worse). 
 
The Consensus Panel warned against trying to change current instruments – 
even if only how the data are displayed (e.g., “flipping the axes” where 
required for symptom scores so that lines going up are always better). 
The Consensus Panel recommends against 
changing the scoring of current instruments.   
Meeting #2 was 
more comfortable 
with the notion of 
changing the 
directionality in 
some situations in 
journal publications. 
PRO data presentation should avoid mixing score direction in a single 
display. 
PRO data presentation should avoid mixing score 
direction in a single display.  In cases where this is 
not possible, authors should consider changing 
the directionality in the display to be consistent. 
Mixed directionality between domains can cause confusion for both 
clinicians and patients. There is a need to address this potential confusion 
by using exceptionally clear labeling, titling, and other annotations.   
There is a need for exceptionally clear labeling, 
titling, and other annotations. 
Meeting #2 did not 
see the need to 
emphasize confusion. 
Conveying 
Score Meaning 
Descriptive labels (e.g., none/mild/moderate/severe) along the y-axis are helpful and should be used when data supporting their 
location on the scale are available. 
 
At a minimum, anchors for the extremes should be included (e.g., 
none/severe), as these labels also help with the interpretation of 
directionality.  Labels for the middle categories (e.g., mild/moderate) 
should be included if evidence is available to support the relevant score 
ranges for each label. 
 Meeting #2 
determined that this 
statement was 
redundant with the 
one above. 
In addition to the descriptive y-axis labels, reference values for comparison 
populations should be included if they are available.   
In addition to the descriptive y-axis labels, reference 
values for comparison populations should be 
considered for inclusion if they are available.   
The change during 
Meeting #2 was 
made to be 
consistent with the 
recommendation for 
displaying reference 
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population norms 
below. 
Score 
Representation 
  
When presenting individual 
patient PRO scores, there is value 
in using consistent representation 
(i.e., line graphs, bar charts, etc.).
   
  Because the display 
of research results is 
driven by the 
analytic strategy, 
both mean scores 
over time and 
proportions were 
addressed for 
research data 
Line graphs are the preferred 
approach for presenting 
individual patient PRO scores 
over time. 
  
Conveying 
Possibly 
Concerning 
Results 
(Absolute 
Scores) 
It is very important to show 
results that are possibly 
concerning in absolute terms, 
assuming the data to support a 
concerning range of results are 
available. 
   
The display of possibly 
concerning PRO results should be 
consistent with how possibly 
concerning results for other 
clinical data (e.g., lab tests) are 
displayed in the institution 
(comparison with other data in 
the electronic health record was 
uniquely considered for this 
issue). 
   
Conveying 
Possibly 
Concerning 
Results 
(Change in 
Score) 
Patients tend to value an 
indication of score worsening that 
is possibly concerning. 
   
Normed 
Scoring 
 PRO data presentation needs to accommodate instruments the way they were developed, with or 
without normed scoring. 
 
 One can decide if/when to show the 
norm visually (with a line on the graph), 
understanding that displaying it might 
provide additional interpretive value, 
but at the cost of greater complexity. 
One can decide if/when to show the reference 
population norm visually (e.g., with a line on the 
graph), understanding that displaying it might 
provide additional interpretive value, but potentially 
at the cost of greater complexity. 
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 Comparison to the norm might be less 
relevant in the context where the 
primary focus is the choice between 
treatments. 
Display of the norm might be less relevant in the 
context where the primary focus is the choice 
between treatments. 
 
 If a norm is displayed: 
• It is necessary to describe the 
reference population and label the norm 
as clearly as possible (recommend 
“average” rather than “norm”) 
• It also requires deciding what 
reference population to show (to the 
extent that options are available).  
• It will need to be explained to 
patients that this normed population 
may not be applicable to a given 
patient. 
If a norm is displayed: 
• It is necessary to describe the reference population 
and label the norm as clearly as possible 
(recommend “average” rather than “norm”). 
• It also requires deciding what reference population 
to show (to the extent that options are available). 
The bolded text was 
seen as appropriate 
for patient 
educational 
materials/decision 
aids, but not for 
journal publications. 
Clinically 
Important 
Differences  
 Patients may find information regarding 
clinically important differences between 
treatments to be confusing, but it is 
important for them to know what 
differences “matter” if they are going to 
make an informed decision. 
Clinically important differences between treatments 
should be indicated with a symbol of some sort 
(described in a legend).  The use of an asterisk is not 
recommended (as it is often used to indicate 
statistical significance).   
 
  If there is no defined clinically important difference, 
that also needs to be in the legend and/or the text of 
the paper. 
 
Conveying 
Statistical 
Significance  
 The data suggest that clinicians and others 
appreciate p-values; however, the Consensus Panel 
recognizes a move away from reporting them (and 
toward the use of confidence limits to illustrate 
statistical significance). Regardless of whether p-
values are reported, confidence intervals should 
always be displayed. 
 
Proportions 
Changed 
 Pie charts are the preferred format 
for displaying proportion meeting a 
responder definition (improved, 
stable, worsened), so long as the 
proportion is also indicated 
numerically. 
Responder analysis results should be displayed 
visually. 
The data supporting 
pie charts were 
stronger for 
presentation to 
patients than for 
presentation to 
clinicians/researchers 
Reasonable options include bar charts, pie 
charts, or stacked bar charts. 
a Underlining indicates minor textual differences between statements across the different applications. 
b Bolding indicates substantive differences between statements across the different applications.
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Table 2: Areas Identified for Future Research 
For all applications: 
• To investigate approaches to address the inherent confusion associated with inconsistency in 
directionality across instruments. 
• To explore whether the evidence supporting better interpretation accuracy and clarity associated with the 
“better” directionality may be informative for future measure development and application.  Specifically, 
to investigate whether, when PROs are used and developed in the future, preference should be given to 
measures where higher scores always indicate better outcomes. 
• To identify the specific score ranges associated with the descriptive y-axis labels (particularly those in 
the middle [e.g., mild, moderate]) for PRO instruments – and the best methods for identifying these 
score ranges.  Specifically, while the extreme categories (e.g., none, severe) can generally be placed at 
the lowest and highest scores, for many PRO measures, the score ranges that would be considered mild 
or moderate, for example, may not have been established.  Research is needed to identify the point 
ranges representing the middle categories (e.g., mild or moderate) for different PRO measures – and to 
identify methods for making these determinations.    
 
For individual-level data 
• To determine if indicating changes greater than the established minimally important difference for the 
instrument would be clinically valued in practice. 
• To determine whether the proportionality of time on the x-axis is an important issue, and if it is, how to 
address it. 
 
For research data presented to patients: 
• To consider how the data indicating challenges with accurately interpreting normed scores may be 
important for clinical implementation.  Specifically, given the evidence demonstrating challenges 
accurately interpreting normed scores for presentation to patients, further research is needed to 
investigate how to handle normed scores for this application of PRO data. 
 
For research data presented to patients and to clinicians/researchers 
• To identify effective approaches for indicating clinically important differences. 
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Appendix Table 1: Meeting Participants  
Name Background & Expertise (at the time of participation) 
PROJECT TEAM 
Claire Snyder, PhD • Principal Investigator  
• Expertise in use of PROs in clinical practice 
Michael Brundage, 
MD, MSc 
• Co-Principal Investigator 
• Practicing radiation oncologist 
• Expertise in use of PROs in clinical practice and clinical trials 
Elissa Bantug, 
MHS* 
• Patient Co-Investigator  
• Breast cancer survivor and advocate 
• Expertise in health communication 
Katherine Smith, 
PhD 
• Co-Investigator  
• Expertise in health communication 
Bernhard Holzner, 
PhD 
• Led previous work on PRO data presentation in Europe 
• Expertise in PROs in clinical practice 
• Associate Editor, Quality of Life Research 
STAKEHOLDER ADVISORY BOARD 
Daniel Weber • Non-Hodgkin’s Lymphoma survivor 
• Director of Communications at the National Coalition for Cancer Survivorship 
Ethan Basch, MD • Practicing medical oncologist 
• Developer of patient-reported toxicity measure 
• Member of PCORI Methodology Committee 
Neil Aaronson, 
PhD 
• Expertise in using PROs in clinical practice 
• Principal Investigator for the development of the EORTC QLQ-C30 quality-of-life 
questionnaire 
• Associate Editor, Journal of the National Cancer Institute 
Bryce Reeve, PhD • Psychometrician 
• Instrumental in the design of the Patient-Reported Outcomes Measurement 
Information System (PROMIS) 
Galina Velikova, 
BMBS(MD), PhD 
• International Society for Quality of Life Research official representative 
• Expertise in using PROs in oncology clinical practice and clinical trials 
• Practicing medical oncologist 
Andrea Heckert, 
PhD, MPH 
• PCORI-nominated staff member  
Eden Stotsky-
Himelfarb 
• Colorectal cancer survivor 
• Nurse working with colorectal cancer survivors 
Cynthia Chauhan† • Breast and renal cell cancer survivor with multiple comorbidities 
• Active research patient advocate 
• Prior and current clinical trial participant 
Vanessa Hoffman, 
MPH 
• Personal caregiving experience to her mother 
• Previous work with the Bladder Cancer Advocacy Network 
Patricia Ganz, MD* • Practicing medical oncologist 
• Developer of the Cancer and Rehabilitation Evaluation System 
• PRO researcher through national clinical trials network 
• Editor-in-Chief, Journal of the National Cancer Institute 
Lisa Barbera, MD, 
MPA† 
• Practicing radiation oncologist 
• Provincial lead of the patient-reported outcomes program at Cancer Care Ontario 
INVITED PARTICIPANTS 
Elizabeth Frank* • Breast cancer survivor and PCORI Patient Ambassador 
• Patient advocate for national committees (e.g., NCI Breast Cancer Steering 
Committee, Patient Advocate Steering Committee) 
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Mary Lou Smith, 
JD† 
• Breast cancer survivor  
• Patient advocate for national clinical trials network committees  
Arturo Durazo • American Cancer Society patient advocate; Blood cancer/NH lymphoma cancer 
survivor  
• Patient advocate for local/state policy, clinical trials, and advisory committees  
• PhD candidate focusing on health communications 
Judy Needham • Breast cancer survivor, retired Communications and Marketing Director 
• Chair, Patient Advocate Committee, Canadian Cancer Trials Group (CCTG); and 
member of various other CCTG committees 
• British Columbia Cancer Agency, Member, Clinical Trials Strategic Advisory 
Committee 
Shelley Fuld Nasso • Chief Executive Officer, National Coalition for Cancer Survivorship 
• Patient advocate 
• Member, NCI National Council of Research Advisors 
Robert Miller, MD • American Society of Clinical Oncology (ASCO) Vice President and Medical Director, 
CancerLinQ® 
Tenbroeck Smith, 
MA 
• American Cancer Society, Strategic Director, Patient-Reported Outcomes 
• PRO researcher 
Deborah Struth, 
MSN, RN, PhD(c) 
• Oncology Nursing Society, Research Associate  
• Work focused in quality measurement and improvement 
• PhD candidate studying cognitive human factors and nursing care outcomes 
Alison Rein, MS • Senior Director, Evidence Generation and Translation - AcademyHealth 
Andre Dias, PhD* • Benchmarking Lead, International Consortium for Health Outcomes Measurement 
(ICHOM) 
• Vice President Strategy & New Program Development 
Charlotte Roberts, 
MBBS, BSc† 
• Vice President of Standardization, International Consortium for Health Outcomes 
Measurement 
Nancy Smider, 
PhD* 
• Epic electronic health record’s Director of Research Informatics  
• Leader of Epic’s annual Research Advisory Council conference 
• Background in biopsychosocial models of health/disease with a focus on patient self-
reports 
Gena Cook* • Chief Executive Officer of Navigating Cancer, a patient relationship management 
technology solution for cancer programs for patient engagement, care management, 
and population health that operates with any EHR system 
• Chair, National Comprehensive Cancer Network (NCCN) Foundation Board 
• Director, Washington Technology Industry Association Benefit Trust 
Jakob Bjorner, MD, 
PhD* 
• Psychometrician 
• Chief Science Officer at Optum 
Holly Witteman, 
PhD* 
• Expertise in decision aids, visualization, and human factors 
James G. Dolan, 
MD* 
• General internist 
• Medical decision-making researcher 
• Clinical decision support researcher and Society of Medical Decision-Making Special 
Interest Group Lead 
Jane Blazeby, MD, 
MSc† 
• Leader of initiatives to standardize the use of PROs in clinical trials 
• Practicing surgeon 
Robert M. Golub, 
MD† 
• Deputy Editor, JAMA 
• General internist 
• Educator in medical decision making and evidence-based medicine 
Christine Laine, 
MD, MPH† 
• Editor in Chief, Annals of Internal Medicine 
• Practicing general internist 
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Scott Ramsey, MD, 
PhD† 
• Associate Editor, Journal of Clinical Oncology 
• Practicing general internist 
*Meeting 1 only; †Meeting 2 only 
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Fig. 1 Graphical Illustration of the Recommendations for Individual Patient Data Line 
Graphs 
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Fig. 2 Graphical Illustration of the Recommendations for Research Data Line Graphs 
Presented to Patients in Educational Materials/Decision Aids 
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Legend: For all graphs, p-values are for between-treatment differences over time, and vertical lines indicate 95% 
confidence limits at each time point. 
† indicates differences between treatments that are clinically important.   
Fig. 3 Graphical Illustration of the Recommendations for Research Data Line Graphs 
Presented to Clinicians in Peer-Reviewed Journal Publications 
 
 
